Evofem Biosciences Inc
OTC:EVFM
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.007
0.016
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
E
|
Evofem Biosciences Inc
F:1AQ1
|
65.8m EUR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -54 647.6% |
| 30th Percentile | 10.3% |
| Median | 17.5% |
| 70th Percentile | 24.9% |
| Max | 2 524.7% |
Other Profitability Ratios
Evofem Biosciences Inc
Glance View
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's sexual and reproductive health. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Evofem Biosciences Inc is -124.1%, which is above its 3-year median of -216.8%.
Over the last 1 years, Evofem Biosciences Inc’s Operating Margin has increased from -346.4% to -124.1%. During this period, it reached a low of -346.4% on Mar 3, 2023 and a high of -108.3% on Dec 31, 2023.